BNP Paribas Exane initiated coverage of Novo Nordisk (NVO) with an Underperform rating and $61 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly (LLY) Stock Jumps as Rival Pfizer Drops Out of Race to Develop Weight Loss Pill
- Novo Nordisk warns of counterfeit Ozempic injections
- Novo Nordisk warns consumers about counterfeit Ozempic injections
- Is Pfizer Stock (PFE) Worth Buying After Its Weight Loss Pill Failure?
- Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill